Correlation analysis of serum FGF9, Sestrin 2 and HBDH with the severity of sepsis
Serum FGF9, Sestrin 2 and HBDH with the severity of sepsis
Abstract
Objective: To explore the correlation between serum fibroblast growth factor 9(FGF9), Sestrin2 and hydroxybutyrate dehydrogenase (HBDH) and the severity of sepsis, and to analyze the predictive value of FGF9, Sestrin2 and HBDH for clinical outcome.
Methods: A retrospective examination of 125 patients with sepsis admitted to our institution between May 2022 and May 2025 was carried out. According to the severity of the disease, There were 50 cases in the septic shock group and 75 cases in the sepsis group. According to the clinical outcomes of the patients, they were divided into a death group of 103 cases and a survival group of 22 cases. Observe the levels of serum FGF9, Sestrin2 and HBDH in each group. Analysis of the relationships between FGF9, Sestrin2, HBDH, and the severity of sepsis was done using the Spearman correlation coefficient model. Using multivariate logistic regression analysis, the factors influencing the prognosis of patients with sepsis were investigated. FGF9, Sestrin2, and HBDH were evaluated for their prognostic usefulness for the prognosis of sepsis patients using the receiver operating characteristic (ROC) curve.
Results: Compared with the sepsis group, The level of FGF9 in the septic shock group was lower [(122.41±21.45) pg/mL vs (145.36±23.68) pg/mL], while the levels of Sestrin2 and HBDH were both higher [(15.75±2.34) ng/mL] vs (8.36 + 0.93) ng/mL, (232.14-34.77) U/L vs (166.25 + 24.85) U/L], the differences were statistically significant (P<0.05). Compared with the survival group, The level of FGF9 in the death group was lower [(112.05±20.61) pg/mL vs (133.25±22.14) pg/mL], while the levels of Sestrin2 and HBDH were both higher [(19.25±2.85)ng/mL] vs (12.42 + 2.33) ng/mL, (261.25-37.25) U/L vs (204.25 + 32.18) U/L]. Spearman correlation coefficient analysis showed that FGF9 was negatively correlated with the severity of sepsis (P<0.05), whereas the degree of sepsis was positively connected with both Sestrin2 and HBDH (P<0.05). Sequential Organ Failure Assessment (SOFA), Acute Physiology and Chronic Health Evaluation II (APACHE II), procalcitonin, FGF9, Sestrin2, and HBDH are risk factors that impact the prognosis of sepsis patients, according to multivariate logistics regression analysis (P<0.05). The results of ROC curve analysis showed that the combined detection of FGF9, Sestrin2 and HBDH had a better predictive effect on the prognosis of patients with sepsis (P<0.05).
Conclusion: The amount of FGF9 in septic shock patients is comparatively low, while the levels of Sestrin2 and HBDH are relatively high. As the severity of the disease increases, the level of FGF9 gradually decreases, while the levels of Sestrin2 and HBDH gradually increase, which have a certain correlation with the severity of the disease. The prognosis of sepsis patients can be ascertained by measuring the levels of FGF9, Sestrin2, and HBDH.
References
2.Li Y, Wan TT, Li JX, Xiao X, Liu L, Li HH, Guo SB. ACE2 Rescues Sepsis-Associated Encephalopathy by Reducing Inflammation, Oxidative Stress, and Neuronal Apoptosis via the Nrf2/Sestrin2 Signaling Pathway. Mol Neurobiol. 2024 Nov;61(11):8640-8655. doi: 10.1007/s12035-024-04063-1. Epub 2024 Mar 27. PMID: 38532242.
3.Tian W, Song P, Zang J, Zhao J, Liu Y, Wang C, Fang H, Wang H, Zhao Y, Liu X, Gao Y, Cao L. Tanshinone IIA, a component of Salvia miltiorrhiza Bunge, attenuated sepsis-induced liver injury via the SIRT1/Sestrin2/HO-1 signaling pathway. J Ethnopharmacol. 2025 Jan 31;340:119169. doi: 10.1016/j.jep.2024.119169. Epub 2024 Nov 29. PMID: 39617088.
4.Williams B, Zou L, Pittet JF, Chao W. Sepsis-Induced Coagulopathy: A Comprehensive Narrative Review of Pathophysiology, Clinical Presentation, Diagnosis, and Management Strategies. Anesth Analg. 2024 Apr 1;138(4):696-711. doi: 10.1213/ANE.0000000000006888. Epub 2024 Feb 7. PMID: 38324297; PMCID: PMC10916756.
5.Legrand M, Bagshaw SM, Bhatraju PK, Bihorac A, Caniglia E, Khanna AK, Kellum JA, Koyner J, Harhay MO, Zampieri FG, Zarbock A, Chung K, Liu K, Mehta R, Pickkers P, Ryan A, Bernholz J, Dember L, Gallagher M, Rossignol P, Ostermann M. Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials. Crit Care. 2024 Mar 21;28(1):92. doi: 10.1186/s13054-024-04877-4. PMID: 38515121; PMCID: PMC10958912.
6.Legrand M, Khanna AK, Ostermann M, Kotani Y, Ferrer R, Girardis M, Leone M, DePascale G, Pickkers P, Tissieres P, Annoni F, Kotfis K, Landoni G, Zarbock A, Wieruszewski PM, De Backer D, Vincent JL, Bellomo R. The renin-angiotensin-aldosterone-system in sepsis and its clinical modulation with exogenous angiotensin II. Crit Care. 2024 Nov 26;28(1):389. doi: 10.1186/s13054-024-05123-7. PMID: 39593182; PMCID: PMC11590289.
7.Siwakoti S, Sah R, Singh RR, Khanal B. Clinical, Bacteriological Profile and Outcome of Neonatal Sepsis. J Nepal Health Res Counc. 2023 Jul 20;20(4):967-972. doi: 10.33314/jnhrc.v20i4.4381. PMID: 37489686.
8.Iyer S, Kennedy JN, Jentzer JC, Senussi MH, Seymour CW. Cardiac Function Before Sepsis and Clinical Outcomes. JAMA. 2024 May 7;331(17):1496-1499. doi: 10.1001/jama.2024.3917. PMID: 38587828; PMCID: PMC11002764.
9.Cao Y, He L, Su Y, Luo J, Ding N. Triglyceride-glucose index and clinical outcomes in sepsis: A retrospective cohort study of MIMIC-IV. J Cell Mol Med. 2024 Aug;28(16):e70007. doi: 10.1111/jcmm.70007. PMID: 39198963; PMCID: PMC11358033.
10.Bhavani SV, Spicer A, Sinha P, Malik A, Lopez-Espina C, Schmalz L, Watson GL, Bhargava A, Khan S, Urdiales D, Updike L, Dagan A, Davila H, Demarco C, Evans N, Gosai F, Iyer K, Kurtzman N, Palagiri AV, Sims M, Smith S, Syed A, Sarma D, Reddy B Jr, Verhoef PA, Churpek MM. Distinct immune profiles and clinical outcomes in sepsis subphenotypes based on temperature trajectories. Intensive Care Med. 2024 Dec;50(12):2094-2104. doi: 10.1007/s00134-024-07669-0. Epub 2024 Oct 9. PMID: 39382693.
11.Ginestra JC, Coz Yataco AO, Dugar SP, Dettmer MR. Hospital-Onset Sepsis Warrants Expanded Investigation and Consideration as a Unique Clinical Entity. Chest. 2024 Jun;165(6):1421-1430. doi: 10.1016/j.chest.2024.01.028. Epub 2024 Jan 19. PMID: 38246522; PMCID: PMC11177099.
12.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
13.Miao S, Liu Y, Li M, Yan J. Clinical subtypes identification and feature recognition of sepsis leukocyte trajectories based on machine learning. Sci Rep. 2025 Apr 10;15(1):12291. doi: 10.1038/s41598-025-96718-9. PMID: 40210965; PMCID: PMC11986166.
14.Zöllner FG, Caroli A, Selby NM. Editorial for "Perfusion and T2 Relaxation Time as Predictors of Severity and Outcome in Sepsis-Associated Acute Kidney Injury: A Preclinical MRI Study". J Magn Reson Imaging. 2023 Dec;58(6):1964-1965. doi: 10.1002/jmri.28696. Epub 2023 Mar 23. PMID: 36951531.
15.Hong G, Ju H, Oh DK, Lee SY, Park MH, Lee H, Lim CM, Lee SI; Korean Sepsis Alliance (KSA) investigators. Clinical characteristics and prognostic factors of sepsis in patients with malignancy. Sci Rep. 2025 Feb 27;15(1):7078. doi: 10.1038/s41598-025-87457-y. PMID: 40016348; PMCID: PMC11932214.
16.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
17.Marsh MC, Lin HM, Black J, Allen K, Weiner B, Ramilo O, Klamer B, Watson JR, Kasick R. Preterm and Term Infants Evaluated for Sepsis: Differences in Management and Clinical Outcomes. Hosp Pediatr. 2023 Jun 1;13(6):544-554. doi: 10.1542/hpeds.2022-007050. PMID: 37222075.
18.Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon. 2024 Mar 28;10(7):e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709.
19.DeMerle KM, Kennedy JN, Chang CH, Delucchi K, Huang DT, Kravitz MS, Shapiro NI, Yealy DM, Angus DC, Calfee CS, Seymour CW. Identification of a hyperinflammatory sepsis phenotype using protein biomarker and clinical data in the ProCESS randomized trial. Sci Rep. 2024 Mar 14;14(1):6234. doi: 10.1038/s41598-024-55667-5. PMID: 38485953; PMCID: PMC10940677.
20.Yao RQ, Shen Z, Ma QM, Ling P, Wei CR, Zheng LY, Duan Y, Li W, Zhu F, Sun Y, Wu GS. Combination of transcriptional biomarkers and clinical parameters for early prediction of sepsis indued acute respiratory distress syndrome. Front Immunol. 2023 Jan 4;13:1084568. doi: 10.3389/fimmu.2022.1084568. PMID: 36685531; PMCID: PMC9846102.
21.Wu L, Li X, Yan J. Commentary: Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. Transl Oncol. 2024 Jul;45:101995. doi: 10.1016/j.tranon.2024.101995. Epub 2024 May 9. PMID: 38789241.
22.Kurul Ş, Beckers FLM, Vermeulen MJ, Suurland J, Hasbek JE, Ramakers CRB, Simons SHP, Reiss IKM, Taal HR. Inflammation, sepsis severity and neurodevelopmental outcomes of late-onset sepsis in preterm neonates. Pediatr Res. 2023 Dec;94(6):2026-2032. doi: 10.1038/s41390-023-02742-8. Epub 2023 Jul 19. PMID: 37468719.
23.Guo Q, Li W, Wang J, Wang G, Deng Q, Lian H, Wang X. Construction and validation of a clinical prediction model for sepsis using peripheral perfusion index to predict in-hospital and 28-day mortality risk. Sci Rep. 2024 Nov 5;14(1):26827. doi: 10.1038/s41598-024-78408-0. PMID: 39501076; PMCID: PMC11538300.
24.Lu Y, Song L. Clinical Significance of Procalcitonin, Lactic Acid, and Endotoxin Testing for Children With Severe Pneumonia and Sepsis. Altern Ther Health Med. 2023 Apr;29(3):218-223. PMID: 36795523.
25.Safabakhsh M, Imani H, Shahinfar H, Mohammadpour M, Rohani P, Shab-Bidar S. Efficacy of dietary supplements on mortality and clinical outcomes in adults with sepsis and septic shock: A systematic review and network meta-analysis. Clin Nutr. 2024 Jun;43(6):1299-1307. doi: 10.1016/j.clnu.2024.03.030. Epub 2024 Apr 10. PMID: 38663051.
26.Lyons PG, McEvoy CA, Hayes-Lattin B. Sepsis and acute respiratory failure in patients with cancer: how can we improve care and outcomes even further? Curr Opin Crit Care. 2023 Oct 1;29(5):472-483. doi: 10.1097/MCC.0000000000001078. Epub 2023 Jul 28. PMID: 37641516; PMCID: PMC11142388.
27.van der Vegt AH, Scott IA, Dermawan K, Schnetler RJ, Kalke VR, Lane PJ. Deployment of machine learning algorithms to predict sepsis: systematic review and application of the SALIENT clinical AI implementation framework. J Am Med Inform Assoc. 2023 Jun 20;30(7):1349-1361. doi: 10.1093/jamia/ocad075. PMID: 37172264; PMCID: PMC10280361.
28.Zhao WT, Herrmann KH, Sibgatulin R, Nahardani A, Krämer M, Heitplatz B, van Marck V, Reuter S, Reichenbach JR, Hoerr V. Perfusion and T2Relaxation Time as Predictors of Severity and Outcome in Sepsis-Associated Acute Kidney Injury: A Preclinical MRI Study. J Magn Reson Imaging. 2023 Dec;58(6):1954-1963. doi: 10.1002/jmri.28698. Epub 2023 Apr 7. Erratum in: J Magn Reson Imaging. 2025 Jan;61(1):524. doi: 10.1002/jmri.29443. PMID: 37026419.
29.Kam KQ, Chen T, Kadri SS, Lawandi A, Yek C, Walker M, Warner S, Fram D, Chen HC, Shappell CN, DelloStritto L, Jin R, Klompas M, Rhee C. Epidemiology and Outcomes of Antibiotic De-escalation in Patients With Suspected Sepsis in US Hospitals. Clin Infect Dis. 2025 Feb 5;80(1):108-117. doi: 10.1093/cid/ciae591. PMID: 39657050; PMCID: PMC11797381.
30.Pohl N, Bauer M, Pancaro C, Cassidy R, Engoren M. Characteristics and Outcomes of Obstetric Sepsis by Three Sets of Clinical Diagnostic Criteria: A Retrospective Study. Am J Perinatol. 2024 May;41(S 01):e3035-e3044. doi: 10.1055/a-2185-3931. Epub 2023 Oct 4. PMID: 37793431.
31.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
32.Chander S, Kumari R, Wang HY, Mohammed YN, Parkash O, Lohana S, Sorath F, Lohana AC, Sadarat F, Shiwlani S. Effect of low vs. high vancomycin trough level on the clinical outcomes of adult patients with sepsis or gram-positive bacterial infections: a systematic review and meta-analysis. BMC Infect Dis. 2024 Oct 7;24(1):1114. doi: 10.1186/s12879-024-09927-4. Erratum in: BMC Infect Dis. 2025 Mar 17;25(1):371. doi: 10.1186/s12879-025-10745-5. PMID: 39375599; PMCID: PMC11457423.
33.MacAllister SA, Fernandez AR, Smith MJ, Myers JB, Crowe RP. Prehospital Sepsis Recognition and Outcomes for Patients with Sepsis by Race and Ethnicity. Prehosp Emerg Care. 2024;28(7):898-904. doi: 10.1080/10903127.2023.2294269. Epub 2023 Dec 22. PMID: 38095600.
34.Moazen J, Zaniani FR, Kassani A, Akhondshushtari P, Ahmadi Z. Prognostic and clinical indicators of sepsis outcomes in hospitalized patients: a cross-sectional study. BMC Infect Dis. 2025 Apr 21;25(1):567. doi: 10.1186/s12879-025-10796-8. PMID: 40259258; PMCID: PMC12010619.
35.Blank JA, King JE, Grant JF, Tian S, Shrestha S, England P, Paje D, Taylor SP. Characteristics, clinical care, and outcomes of sepsis among patients boarding in the emergency department. J Hosp Med. 2025 Apr;20(4):368-373. doi: 10.1002/jhm.13536. Epub 2024 Oct 27. PMID: 39462682; PMCID: PMC11963743.
Copyright (c) 2025 Jian He, Xinru Lin, Xiang Ding, Maoxia Liu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.